Skip to Content

Teniposide Dosage

Applies to the following strength(s): 10 mg/mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Acute Lymphocytic Leukemia

For use in the treatment of patients with refractory childhood acute lymphoblastic leukemia:

Patients failing induction therapy with a cytarabine-containing regimen:
165 mg/m² by slow IV infusion and 300 mg/m² cytarabine IV twice weekly for 8 to 9 doses.

Patients refractory to vincristine/prednisone-containing regimens:
250 mg/m² by slow IV infusion and 1.5 mg/m² vincristine IV weekly for 4 to 8 weeks with 40 mg/m² prednisone orally for 28 days.

Usual Adult Dose for non-Hodgkin's Lymphoma

30 mg/m2/day for 10 days

or

50 to 100 mg/m2 once a week as a single agent

or

60 to 70 mg/m2/day once a week in combination with other chemotherapeutic agents

Usual Pediatric Dose for Acute Lymphoblastic Leukemia

In combination with other approved anticancer agents, teniposide is indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia in the following regimens:

Patients failing induction therapy with a cytarabine-containing regimen:
165 mg/m² by slow IV infusion and 300 mg/m² cytarabine IV twice weekly for 8 to 9 doses.

or

Patients refractory to vincristine/prednisone-containing regimens:
250 mg/m² by slow IV infusion and 1.5 mg/m² vincristine IV weekly for 4 to 8 weeks with 40 mg/m² prednisone orally for 28 days.

or

165 mg/m2 by slow IV infusion on days 1 and 2 of weeks 3, 13, and 23

Renal Dose Adjustments

There is insufficient data and there are no specific dose adjustment recommendations. However, dose adjustments may be necessary.

Liver Dose Adjustments

There is insufficient data and there are no specific dose adjustment recommendations. However, dose adjustments may be necessary.

Dose Adjustments

Patients with Down syndrome and leukemia may be more sensitive to the myelosuppressive effects. Therefore, the first course should be administered at half the usual dose and the dose should be adjusted in subsequent cycles upward based on degree of toxicities (myelosuppression and mucositis) in the previous course(s).

Precautions

Teniposide should be administered over at least 30 to 60 min.

Do not give by rapid IV injection.

Hemoglobin, WBC, and platelets should be closely monitored. Dose limiting bone marrow suppression is the most significant toxicity associated with teniposide therapy.

Dialysis

There is insufficient data and there are no specific dose adjustment recommendations. However, dose adjustments may be necessary.

Hide